Savara
SVRA
About: Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Employees: 59
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
25,400% more call options, than puts
Call options by funds: $255K | Put options by funds: $1K
31% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 36
1.35% more ownership
Funds ownership: 95.63% [Q1] → 96.98% (+1.35%) [Q2]
10% less funds holding
Funds holding: 134 [Q1] → 121 (-13) [Q2]
16% less capital invested
Capital invested by funds: $457M [Q1] → $382M (-$75.1M) [Q2]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]
50% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 26
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
|
Guggenheim
Vamil Divan
|
$11
|
Buy
Maintained
|
9 Sep 2025 |
|
Oppenheimer
Andreas Argyrides
|
$8
|
Outperform
Maintained
|
8 Sep 2025 |
|
HC Wainwright & Co.
Andrew S. Fein
|
$8
|
Buy
Maintained
|
3 Sep 2025 |
|
Oppenheimer
Francois Brisebois
|
$6
|
Outperform
Maintained
|
15 Aug 2025 |
Financial journalist opinion
Based on 38 articles about SVRA published over the past 30 days
